A study of microPET for assessing regional cerebral glucose metabolism and the expression of dopamine receptor type 2 in a rat model of Parkinson's disease

• Published in: Zhong hua yi xue za zhi Vol. 91; no. 29; p. 2068
• Main Authors: Li, Tian-lang, Xu, Jian-Fei, Wang, Jing, Zhang, Hong, Mao, Shan-ying, Wen, Shu-qun, Zhou, Yan
• Format: Journal Article
• Language: Chinese
• Published: China 09.08.2011
• Subjects: Animals; Cerebral Cortex - diagnostic imaging; Cerebral Cortex - metabolism; Disease Models, Animal; Glucose - metabolism; Male; Parkinson Disease - diagnostic imaging; Parkinson Disease - metabolism; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2 - metabolism
• ISSN: 0376-2491
• DOI: 10.3760/cma.j.issn.0376-2491.2011.29.014

To employ (18)F-fluoro-2-deoxyglucose ((18)F-FDG) and (3-N-[(11)C] methylspiperone)(11)C-NMSP microPET to assess the changes of regional cerebral glucose metabolism and the expression of dopamine receptor type 2 (DRD(2)) in a rat model of Parkinson's disease (PD). A hemiparkinsonian model was established in rats by unilateral pretreatment with 6-hydroxydopamine (6-OHDA). At 2 weeks after 6-OHDA insult, (18)F-FDG and (11)C-NMSP microPET scan were performed to compare the differences of regional cerebral glucose metabolism and the expression of DRD(2) between the PD and control groups respectively. The immunohistochemical staining was used to detect the expression of tyrosine hydroxylase in two groups. In the PD model, the glucose metabolism rates were 88.2% ± 2.2%, 94.5% ± 4.5% and 96.2% ± 5.8% respectively, in right striatum, hippocampus and sensorimotor cortex. And they were significantly lower than those in the control group [92.7% ± 2.8% (P < 0.01), 98.9% ± 3.9% (P < 0.01) & 102.8% ± 2.1% (P < 0.01)]. The